About Exosiris

Exosiris is pioneering the next generation of nanomedicine through advanced extracellular vesicle platforms designed for targeted therapeutic delivery. Our mission is to transform the way complex diseases are treated by providing safe, precise, and scalable solutions. By harnessing the unique properties of this technology we aim to unlock innovative treatments in oncology, regenerative medicine, and autoimmune disorders, areas where current therapies often fall short.

At Exosiris, we are committed not only to scientific excellence but also to making advanced therapies accessible worldwide, bridging the gap between cutting-edge research and real patient needs.making advanced therapies accessible worldwide.

woman in white shirt holding blue and white plastic toy
woman in white shirt holding blue and white plastic toy
Democratization of therapies for unmet clinical needs, transforming healthcare together

Pioneering a new generation of nanomedicine for precise and minimally invasive therapeutic delivery

a close up of a wave on a beach

Scientific Co-Founders & Advisors

Julien Caumartin, Ph.D. – CEO
IImmunologist with nearly 20 years advancing the understanding of the tumor microenvironment and tumor–immune evasion. Co-developer of the first anti-HLA-G CAR-T cells (in clinical trial at MD Anderson) and a driver of novel CAR strategies against complex tumor antigens. Renowned for bridging fundamental immunology and translational innovation, he leads next-generation therapy development in pharma, with deep expertise in immune checkpoint pathways and a strong track record in scientific leadership, strategic direction, and partnerships.

Chantal Pichon, Ph.D. is a globally recognized leader in mRNA therapeutics and nanomedicine whose pioneering contributions have helped advance the field of RNA-based medicines. As Professor at the University of Orléans and Head of the ART-mRNA team at the CNRS Centre for Molecular Biophysics, she spearheads innovative research in non-viral nucleic acid delivery and translational medicine. Her work is at the forefront of next-generation therapeutic technologies, accelerating the development of safer and more effective treatments for patients worldwide.

Leadership Team

Maria Loustau, Ph.D. – CSO
Biotech leader with 15+ years in biotech R&D and strategic management. Developer of first-in-class anti-HLA-G CAR-T cells and a pioneer in antibodies, nanobodies, and checkpoint targets. Co-inventor on seven patents, recipient of CPRIT funding, and twice recognized by MATWIN for innovation. Brings deep expertise in next-generation therapy development, leading multidisciplinary teams and translational partnerships with a strong strategic vision. Committed to scientific excellence and focused on translating breakthroughs into impactful patient therapies.

Florence Gazeau, Ph.D. is an internationally recognized leader in nanomedicine, renowned for pioneering research at the crossroads of physics, biology, and translational medicine. As Research Director at CNRS and Head of the NABI Laboratory (Nanomedicine, Extracellular Biology, Integratome and Health Innovations), a joint unit of Université Paris Cité, CNRS, and Inserm, she is shaping the future of precision medicine and next-generation biotherapies. Dr. Gazeau is advancing innovative therapeutic strategies that bridge fundamental science and clinical application, accelerating the development of transformative healthcare solutions.

Lucile Alexandre, Ph.D. is a leading French researcher at the forefront of biophysics, nanotechnology, and extracellular vesicle engineering. Her work bridges physics, biology, and nanomedicine to develop innovative therapeutic and diagnostic platforms that address some of the most pressing challenges in modern healthcare. With recognized expertise in extracellular vesicles (EVs), exosomes, and advanced drug delivery systems, Dr. Alexandre is driving the development of next-generation technologies that unlock new possibilities for precision medicine and translational healthcare.

Innovative Hybrid Nanoplatform

Transforming medicine with targeted in vivo therapies.

Access

Future

contact@exosiris.com

+33623502612